Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, the Company is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
Type
Public
HQ
South San Francisco, US
Founded
2001
Size (employees)
15 (est)-11%
Threshold Pharmaceuticals was founded in 2001 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Threshold Pharmaceuticals

Harold Selick

Harold Selick

CEO
Tillman Pearce

Tillman Pearce

Chief Medical Officer

Threshold Pharmaceuticals Office Locations

Threshold Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
300 170 Harbor Way
Show all (1)
Report incorrect company information

Threshold Pharmaceuticals Financials and Metrics

Threshold Pharmaceuticals Financials

USD

Revenue (Q3, 2017)

648 k

Net income (Q3, 2017)

(11 m)

EBIT (Q3, 2017)

(5.9 m)

Market capitalization (22-Jun-2018)

154.2 m

Cash (30-Sep-2017)

68.2 m

EV

90.1 m
Threshold Pharmaceuticals's current market capitalization is $154.2 m.
Annual
USDFY, 2016

General and administrative expense

7.8 m

R&D expense

16.6 m

Operating expense total

24.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

3.7 m3.7 m3.7 m3.7 m3.7 m3.7 m3.7 m648 k

General and administrative expense

2.5 m2.4 m2.6 m2.5 m2.4 m2.2 m1.9 m1.7 m2.9 m4 m

R&D expense

8.7 m8.9 m10.7 m10.1 m8.1 m6 m4 m3.5 m1.6 m2.5 m

Operating expense total

11.1 m11.3 m13.3 m12.6 m10.5 m8.3 m5.9 m5.2 m4.4 m6.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

7.3 m8.4 m9.6 m10.6 m

Inventories

2.2 m832 k2.6 m623 k

Current Assets

86 m66.7 m53.2 m24.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Cash

6.5 m11.2 m21.1 m10.6 m13.7 m11.2 m12.4 m15.2 m11.4 m68.2 m

Accounts Receivable

38 k

Inventories

1.4 m

Current Assets

70.1 m74.1 m82.1 m72.2 m62.2 m40.6 m35.8 m29.5 m20 m69.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.4 m)(21.6 m)43.8 m(24.1 m)

Depreciation and Amortization

1.5 m1.3 m1 m423 k

Inventories

(1.1 m)1.3 m(774 k)2.1 m

Accounts Payable

781 k385 k(1.3 m)97 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(766 k)(7.7 m)(11.2 m)(8.3 m)(6.4 m)(7.9 m)(6.9 m)(5.7 m)(5.1 m)

Accounts Payable

2.9 m3.4 m1.8 m635 k436 k1.6 m3.1 m699 k328 k
USDY, 2017

EV/EBIT

-15.4 x

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information